Core Viewpoint - Haizheng Pharmaceutical reported significant growth in revenue and net profit for the third quarter of 2025, indicating strong operational performance and advancements in various business segments [1][2]. Financial Performance - The company achieved a total revenue of 7.923 billion yuan and a net profit attributable to shareholders of 461 million yuan in the first three quarters [1]. - In Q3 alone, revenue reached 2.672 billion yuan, with a net profit of 162 million yuan, marking a year-on-year increase of 102.14% [1]. - The non-recurring net profit for Q3 was 169 million yuan, up 96.13% year-on-year [1]. - The gross profit margin improved by 3.81 percentage points, while the expense ratio decreased by 1.35 percentage points [1]. - Net cash flow from operating activities increased by 12.99% year-on-year [1]. Business Segments - The pharmaceutical formulation sector made significant strides, with the launch of the combination therapy for ACS patients setting a new standard in lipid-lowering treatment [1]. - The product "Meiman" was included in the 2025 edition of the guidelines for treating pediatric pneumonia, becoming a recommended medication for resistant Mycoplasma pneumonia [1]. Raw Material and Innovation - The raw material drug for bedaquiline received approval from the National Medical Products Administration, marking a major advancement in the development of key drugs for multidrug-resistant tuberculosis [2]. - The company became the first in China and the fourth globally to receive European Pharmacopoeia suitability certification for tigecycline raw materials [2]. - In the pet medicine sector, the product "Haili Miao" celebrated its tenth anniversary with over 45 million units sold, achieving recognition as the top-selling cat internal medicine in China [2]. Research and Internationalization - R&D expenses increased by 1.36 percentage points year-on-year, with the company obtaining clinical trial approval for HS387, a selective KIF18A inhibitor for treating advanced solid tumors [2]. - The EU has removed the GMP non-compliance statement for the Taizhou factory, enhancing the company's competitiveness in the global pharmaceutical supply chain [2]. Strategic Collaborations - The company entered a collaboration with Aixin Dawei in the SMDC field, incorporating HSE-001 into its R&D pipeline [3]. - A joint venture with Zhejiang Shengzhao Pharmaceutical Technology Co., Ltd. is planned to focus on the development and commercialization of 11 complex injectable products [3]. Future Outlook - As 2025 approaches its end, the company aims to deepen strategic initiatives, enhance domestic and international collaborations, and explore innovative fields to strengthen its market position in the pharmaceutical industry [3].

Core Insights - Haizheng Pharmaceutical reported a strong performance in Q3 2025, achieving a total revenue of 7.923 billion yuan and a net profit of 461 million yuan for the first three quarters, with Q3 alone generating 2.672 billion yuan in revenue and 162 million yuan in net profit, marking a year-on-year increase of 102.14% [1] - The company achieved its best-ever performance in terms of non-recurring net profit since its listing, with significant improvements in operational quality, including a gross margin increase of 3.81 percentage points and a decrease in expense ratio by 1.35 percentage points [1] Business Performance - In the pharmaceutical formulation sector, the core product, Saismei (generic name: Haibomai Tablets), has become the new standard for lipid-lowering treatment in acute coronary syndrome (ACS) patients, enhancing brand recognition [2] - The product "Meiman" has been included in the 2025 edition of the "Guidelines for the Diagnosis and Treatment of Pediatric Pneumonia Caused by Mycoplasma," solidifying its position in community infection treatment [2] - In the active pharmaceutical ingredient (API) sector, the approval of fumarate bedaquiline API marks a significant advancement in the development of key drugs for multidrug-resistant tuberculosis [2] Innovation and Internationalization - The synthetic biology subsidiary, Yunseng, successfully launched a flexible production line and established a strategic partnership with Jiangnan University to accelerate the industrialization of technological achievements [3] - The company’s Taizhou factory has had its GMP non-compliance status removed by the EU, enhancing its core competitiveness in the global pharmaceutical supply chain [3] R&D Investment - Haizheng Pharmaceutical has increased its R&D expenditure ratio by 1.36 percentage points in the first three quarters, with the innovative drug HS387 (a selective KIF18A inhibitor) receiving clinical trial approval for treating advanced solid tumors [4] - The company announced a joint investment with Zhejiang Shengzhao Pharmaceutical Technology Co., Ltd. to establish a joint venture focused on complex injectable products, aiming to enhance its capabilities in R&D, production, and commercialization in this field [4]

Group 1 - The US and China held talks in Madrid on September 14 regarding trade issues, including US unilateral tariff measures and export controls [4] - The Ministry of Industry and Information Technology and seven other departments issued the "Automobile Industry Stabilization Growth Work Plan (2025-2026)" [2][11] - The Shanghai Stock Exchange announced the candidate list for the third Technology Innovation Advisory Committee, including notable entrepreneurs [2][5] Group 2 - The broad money supply (M2) increased by 8.8% year-on-year in August, with non-bank financial institutions' deposits increasing by 550 billion yuan [5] - The National Internet Information Office released a draft for public consultation on promoting and regulating electronic document applications, proposing the exploration of digital RMB for cross-border payments [5] - The film market's box office for 2025 has surpassed 40 billion yuan as of September 13, 2025, 76 days ahead of 2024 [5] Group 3 - The first project of the third phase of the National Integrated Circuit Industry Investment Fund targets semiconductor equipment, with a capital increase of 4.5 billion yuan for Tuojing Technology [10] - Domestic semiconductor equipment has shown strong growth trends, with the market expected to maintain a long-term scale of over 40 billion USD [10] Group 4 - The "Automobile Industry Stabilization Growth Work Plan" aims to promote the industrial application of intelligent connected technology, with a projected industry value increase of 725.9 billion yuan by 2025 [11] - The plan encourages the development of new business models using data and supports the production of L3-level vehicles [11][13] Group 5 - The "New Energy Storage Scale Construction Special Action Plan (2025-2027)" aims for a new energy storage installation scale of over 180 GW by 2027, driving direct investment of about 250 billion yuan [14][15] - Companies like Haibo Technology and Sungrow Power have reported significant revenue growth in their energy storage systems [15] Group 6 - TCL Technology plans to invest approximately 29.5 billion yuan to build an 8.6-generation printed OLED production line [17] - Haizheng Pharmaceutical has received a CEP certificate for its Tigecycline raw materials, marking a significant step for international market expansion [19] - Zhongchao Holdings signed a strategic cooperation agreement with Hefei Intelligent Robot Research Institute to promote applications in intelligent robotics [20]

Group 1 - The company Zhejiang Haizheng Pharmaceutical Co., Ltd. has received the Certificate of Suitability to Monograph of European Pharmacopoeia (CEP) for the active pharmaceutical ingredient Tigecycline from the European Directorate for the Quality of Medicines & HealthCare (EDQM) [1][2] - The CEP certificate indicates that the quality of Tigecycline is recognized by European standards, allowing the product to enter the EU market and other markets that acknowledge the CEP certificate, which positively impacts the company's international market expansion [2] - The global sales volume of Tigecycline active pharmaceutical ingredient is projected to be approximately 601.30 kilograms in 2024 and around 290.22 kilograms for the first half of 2025, according to IQVIA data [1] Group 2 - The company is the first domestic enterprise to obtain the CEP certificate for Tigecycline active pharmaceutical ingredient, highlighting its competitive position in the market [1] - Tigecycline is primarily used for treating infections caused by specific bacterial strains in patients over 18 years old, including complicated intra-abdominal infections, complicated skin and soft tissue infections, and community-acquired bacterial pneumonia [1] - The international active pharmaceutical ingredient business is subject to changes in overseas market conditions and exchange rate fluctuations, which may impact the company's operations [2]

Core Viewpoint - The company, Haizheng Pharmaceutical, has received the Certificate of Suitability to Monograph of European Pharmacopoeia (CEP certificate) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its Tigecycline active pharmaceutical ingredient [1] Group 1 - The CEP certificate indicates that Tigecycline is suitable for use in treating infections caused by specific sensitive strains of bacteria in patients aged 18 and above [1] - Tigecycline is primarily indicated for the treatment of complex intra-abdominal infections, complex skin and soft tissue infections, and community-acquired bacterial pneumonia [1]

Core Viewpoint - Haizheng Pharmaceutical has received the CEP certificate for Tigecycline raw materials from the European Medicines Agency, marking it as the first domestic company to achieve this certification, which enhances its qualifications for entering the EU and other markets that recognize the CEP certificate [1] Group 1 - The receipt of the CEP certificate signifies recognition and affirmation of the quality of the raw material by the European regulatory market [1] - This certification allows the company to expand its international market presence positively [1]

Core Viewpoint - The company has received the CEP certificate for tigecycline active pharmaceutical ingredient from the European Directorate for the Quality of Medicines and HealthCare (EDQM), marking a significant achievement as the first domestic enterprise to obtain this certification [1] Group 1 - The global sales volume of tigecycline active pharmaceutical ingredient is approximately 290.22 kilograms for the period from January to June 2025 [1]